<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2022">
  <stage>Registered</stage>
  <submitdate>25/06/2008</submitdate>
  <approvaldate>25/06/2008</approvaldate>
  <nctid>NCT00705939</nctid>
  <trial_identification>
    <studytitle>Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial</studytitle>
    <scientifictitle>A Multicenter, Double-Blind, Extension Trial of Two Parallel Dose Groups of Plant Cell Expressed Recombinant Human Glucocerebrosidase (prGCD) in Patients With Gaucher Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>PB-06-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gaucher Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Taliglucerase alfa

Experimental: Naive 30 Units/kg - Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)

Experimental: Naive 60 Units/kg - Continue taliglucerase alfa treatment from PB-06-001 (NCT00376168)

Experimental: Switchover - Continue taliglucerase alfa treatment from PB-06-002 (NCT00712348)


Treatment: drugs: Taliglucerase alfa
Intravenous infusion every 2 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Spleen Volume - Spleen volume measured by MRI</outcome>
      <timepoint>Spleen Volume at Baseline and Months 12, 24, and 36</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Liver Volume - Liver volume measured by MRI</outcome>
      <timepoint>Liver volume at Baseline and Months 12, 24 and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hemoglobin</outcome>
      <timepoint>Hemoglobin at Baseline and Months 12, 24 and 36</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Platelet Count</outcome>
      <timepoint>Platelet count at Baseline and Months 12, 24 and 36</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Successful completion of Protocol PB-06-001

          -  The patient signs informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Currently taking another experimental drug for any condition

          -  Presence of severe neurological signs and symptoms, defined as complete ocular
             paralysis, overt myoclonus or history of seizures, characteristic of neuronopathic
             Gaucher disease

          -  Pregnant or nursing

          -  Presence of any medical, emotional, behavioral or psychological condition that in the
             judgment of the Investigator would interfere with the patient's compliance with the
             requirements of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional(has expanded access)</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>45</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Bone Marrow Transplant Service, The Royal Melbourne Hospital - Parkville</hospital>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Morningside</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Zaragoza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Protalix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the
      human glucocerebrosidase gene (GCD) leading to reduced activity of the lysosomal enzyme
      glucocerebrosidase and thereby to the accumulation of substrate glucocerebroside (GlcCer) in
      the cells of the monocyte-macrophage system.

      This is an extension trial to Study NCT00376168 and NCT00712348.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00705939</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ari Zimran, MD</name>
      <address>Shaare Zedek Medical Center, Jerusalem, Israel</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>